• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

New Drug Safety Alliance, Website to Educate on REMS

Article

Pharmaceutical Executive

October 22, 2015.

A new alliance has launched to educate the public, policymakers and other key stakeholders about Risk Evaluation and Mitigation Strategies (REMS). The Patients Alliance for Drug Safety Protections is comprised of 20 public health, patient advocacy, health professional and disease organizations. To underscore the value of REMS to public health, the Alliance unveiled a new online resource, www.drugprotections.org that translates the latest facts about the REMS program in layman's terms. Designed for ease of use, the online hub summarizes the history and purpose of REMS, what REMS entails and the number of medicines now marketed with a REMS. In addition, the website provides links to information about REMS from FDA and other reputable source and will serve as a clearinghouse for the coalition's policy materials. 

Read the full release.

 

Related Videos
Ashley Gaines
Related Content
FDA Grants Priority Review Biologics License Application to Dupixent Add-On Maintenance for the Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis

FDA Grants Priority Review Biologics License Application to Dupixent Add-On Maintenance for the Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis

May 13th 2024
Article

Dupixent has previously been approved for adults with chronic rhinosinusitis with nasal polyposis whose condition is inadequately controlled.

A Biosimilars Roadmap: Understanding Payer Perceptions

A Biosimilars Roadmap: Understanding Payer Perceptions

May 13th 2024
Article

With competition for follow-on-biologics on the upswing—and a potential market boom perhaps around the corner—continued education and course-setting for all stakeholders in charting the access landscape is paramount.

Avoiding the Digital Age is Hurting Research Efforts

Avoiding the Digital Age is Hurting Research Efforts

May 10th 2024
Article

A greater shift from paper records and physical assets is achievable.

FDA Approves Two of Scientia Vascular’s Neurovascular Catheters

FDA Approves Two of Scientia Vascular’s Neurovascular Catheters

May 7th 2024
Article

The catheters approved by the FDA include the Plato 17, a DMSO-compatible microcatheter, and the Socrates 38, an aspiration catheter specifically designed for treating ischemic strokes.

Peter Ax

Solving the Prescription Drug Shortage: Q&A with Peter Ax

May 7th 2024
Article

The founder and CEO of UpScriptHealth discusses the issues causing the shortage and how recent decisions from the DEA may help solve the issue.

FDA Approves Azurity Pharmaceuticals’ Myhibbin as an Oral Suspension for Organ Transplant Recipients

FDA Approves Azurity Pharmaceuticals’ Myhibbin as an Oral Suspension for Organ Transplant Recipients

May 6th 2024
Article

Myhibbin is reportedly the first FDA-approved liquid formulation of mycophenolate, a key immunosuppressant used to prevent organ rejection in transplant recipients.